Efficacy of S-1 in colorectal cancer

@article{Miyamoto2014EfficacyOS,
  title={Efficacy of S-1 in colorectal cancer},
  author={Yuji Miyamoto and Yasuo Sakamoto and Naoya Yoshida and Hideo Baba},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={1761 - 1770}
}
Introduction: S-1 is an oral fluoropyrimidine that consists of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate. It has been developed as a prodrug of 5-fluorouracil with the goal of improving therapeutic efficacy and tolerability. Areas covered: This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional… 
TAS-102 an Emerging Oral Fluoropyrimidine.
TLDR
This review summarizes recent progress with regard to TAS-102, a newly-developed anti-folate drug containing the 5-FU analogue trifluridine and tipiracil hydrochloride and thus increases the bioavailability of TFD, and proposes several approaches to further improve the efficacy.
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)
TLDR
The findings suggest that the combination of S-1 and irinotecan plus bevacizumab is effective and tolerable as second-line chemotherapy for patients with oxaliplatin-refractory mCRC.
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma
TLDR
The combination of S-1 plus cisplatin was a well-tolerated and convenient chemotherapy regimen with promising efficacy and Toxicity was mild to moderate and generally tolerable.
Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer.
TLDR
The optimal chemotherapy treatment regimen containing pemetrexed + S-1 + bevacizumab was found to be the optimal combination and was superior to the other treatment regimens in terms of DCR and PFS with controllable toxicity.
Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses
TLDR
A novel treatment strategy for those patients with advanced colorectal cancer who experience cardiotoxic reactions to fluoropyrimidines, the active agent of gold standard treatment is summarised.
Oral drugs in the treatment of metastatic colorectal cancer
TLDR
Oral fluoropyrimidines such as capecitabine, as monotherapy or in combination with oxaliplatin, irinotecan or bevacizumab, are as effective as intravenous 5-fluorouracil (5-FU) in first-line treatment of mCRC.
Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)
TLDR
In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was…………, followed by a 1-week drug-free interval” should read as,”.
Oral versus intravenous fluoropyrimidines for colorectal cancer.
TLDR
The efficacy and safety of oral and IV fluoropyrimidines for treatment of colorectal cancer (CRC) and the use of intention-to-treat analysis in patients treated with curative or palliative intent was compared.
Effect of Metabolic Inhibitors on the Hepatic Disposition of 5-Fluorouracil after Application to the Rat Liver Surface.
TLDR
It is demonstrated that applying 5-FU with gimeracil to the rat liver surface could increase the availability of 4-fluorouracil in the liver, and the area under the5-FU concentration-time curve at site 1 was 3.4 times greater than that of the control.
...
...

References

SHOWING 1-10 OF 64 REFERENCES
Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
TLDR
It is suggested that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
TLDR
It is suggested that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
  • A. Goto, Y. Yamada, K. Shirao
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
It is suggested that combined treatment with S-1 and irinotecan is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer.
Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients
Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal
Development History and Concept of an Oral Anticancer Agent S-1 (TS-1®): Its Clinical Usefulness and Future Vistas
  • T. Shirasaka
  • Medicine, Biology
    Japanese journal of clinical oncology
  • 2009
TLDR
‘S-1 and low-dose cisplatin therapy’ without provoking Grade 3 non-hematologic toxicities was proposed to enhance its clinical usefulness and ‘alternate-day S-1 regimen’ may improve the dosing schedule for 5-FU by utilizing its strongly time-dependent mode of action.
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
TLDR
The SIRB regimen appears to be highly active and well tolerated as first-line treatment for mCRC patients and has a very low incidence of hand-foot syndrome.
Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis
TLDR
Both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.
Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
TLDR
Combined treatment with S-1 and irinotecan is an effective, well-tolerated and convenient regimen in patients with advanced colorectal cancer which is easily maintained.
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
  • J. Ajani, J. Faust, P. Urrea
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
At the established MTD of S-1 plus cisplatin, the S- 1 dose is lower in this study than in the Japanese study (80 mg/m2/d for 21 days) and a multi-institutional phase II study of this active combination is currently accruing patients.
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer
TLDR
Irinotecan with continuous infusional 5-fluorouracil with S-1 (IRIS) is an effective, well tolerated and convenient treatment regimen for patients with advanced colorectal cancer.
...
...